Vaccine Administration. (1) Vaccines must be administered as directed in the most current, signed version of OHA’s Model Standing Orders for Immunizations.
Vaccine Administration. Pharmacists, as authorized pursuant to a collaborative practice agreement, may administer vaccines.
Vaccine Administration. During an influenza pandemic, it is possible that persons of all ages will need multiple doses of pandemic vaccine separated by recommended time intervals in order to mount an appropriate level of immune response to be protected from pandemic virus infection. It may also be possible that adjuvant would be required in each pandemic vaccine dose, with the need to be mixed at the point of administration to patient. Furthermore, it may be possible that only certain types or brands of adjuvant will be approved for use with certain types or brands of pandemic vaccine antigen. Also, many patients will likely receive their first and second pandemic vaccine dose from different providers at different locations. These complexities will make the need for complete and accurate vaccine administration documentation extremely important for patient safety, so that all pandemic vaccine providers are able to access this documentation to correctly assess and therefore correctly match pandemic vaccines and adjuvants between doses in each patient.
Vaccine Administration. (1) Section 317 vaccines may only be administered to recipients determined to be eligible according to the most current vaccine eligibility chart, available at xxxxx://xxx.xxxxxx.xxx/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATIO N/IMMUNIZATIONPROVIDERRESOURCES/Documents/317chart.pdf.
Vaccine Administration. Provided to applicants and employees identified by their job title, or California Code of Regulations Title 8, Section 5193, or communicable disease exposure notification. Vaccinations may be provided by EHS or the County’s contracted provider.
Vaccine Administration. During a pandemic, it is possible that persons of all ages will need multiple doses of pandemic vaccine separated by recommended time intervals in order to acquire an appropriate level of immune response to be protected from pandemic virus infection. Also, many patients will likely receive their first and second pandemic vaccine dose from different providers at different locations. These complexities will make the need for complete and accurate vaccine administration documentation extremely important for patient safety, so that all pandemic vaccine providers are able to access this documentation to correctly determine the need for vaccination.
Vaccine Administration. Vaccines shallwill be administered Annually in accordance with a schedule determined by OHA in consultation with LPHA or as requested by OHA, LPHA shall submit a duly executed Immunization Program Public Provider Agreement and Public Provider Profile, both of which are requirements of CDC for any LPHA that receives State-Supplied Vaccine/IG. LPHA shall comply with the terms and conditions of the Public Provider Agreement. OHA will maintain and have available for review the signed Immunization Program Public Provider Agreement and Public Provider Profile at the OHA’s office located at 000 XX Xxxxxx Xx, Xxxxx 000, Xxxxxxxx, XX 00000. All State-Supplied Vaccine/IG must be offered to appropriate clients and may only be administered in accordance with the current recommendations of the Department of Health and Human Services’ Advisory Committee on Immunization Practices (ACIP) and OHA’s Communicable Disease Summaries, as directeds summarized in the most current, signed version of OHA’s Model Standing Orders for VaccinesImmunizations. LPHA will ensure that clinical immunization staff annually view the Epidemiology and Prevention of Vaccine-Preventable Diseases program or the annual update. Both are available as a DVD or a web-on-demand from the CDC’s website., and in accordance with the Standards for Child and Adolescent Immunization Practices and the Standards for Adult Immunization Practices. These documents and standards are available for review at: xxxx://0.xxx.xxx/ImmunizationProviderResources. In connection with the administration of a vaccine, LPHA must: Confirm that a recipient, parent, or legal representative has read, or has had read to them, the VIS and has had their questions answered prior to the administration of the vaccine. Make the VIS available in other languages or formats when needed (e,ge.g., when English is not a patient’s primary language or for those needing the VIS in braille.) Provide to the recipient, parent or legal representative, documentation of vaccines received at visit. LPHA may provide a new immunization record or update the recipient’s existing handheld record. Screen for contraindications and precautions prior to administering vaccine. and document that screening has occurred. Document administration of an immunization using a vaccine administration record or electronic equivalent in a permanent file, including all federally-required charting elements. (Note- ALERT IIS does not record all federally-required elements and is no...
Vaccine Administration. (1) LPHACHS must administer vaccines as directed in the most current, signed version of OHA’s Model Standing Orders for Immunizations. CHS’ Medical Director will adopt and sign model standing orders published by XXX.
Vaccine Administration. Briefly, Ab derivative is added to aluminum adjuvant which is approved for human use, to a concentration of 1 mg/ml. Young and old lemurs (n=5-6 per group) receive a subcutaneous injection of 100 µl of the mixture or adjuvant alone followed by a second injection two weeks later and then monthly thereafter. The young animals will periodically go through long intervals (up to 6 months) without vaccination to determine the reversibility of the immune response which has important safety implications. The same issue will be assessed once in the old primates. Treatment groups: 1) K6Ab1-30, which in mice elicits a strong IgG response [3;4]; 2) K6Ab1-30[E18E19], which in mice results primarily in an IgM response [5]; 3) Ab1-30[E18E19], which is not very immunogenic in mice [5], and; 4) Ab1-42 and 5) Adjuvant alone as controls. The young animals (<2 years old) will not have developed any AD pathology [2]. Many of the old mouse lemurs (>7 years old), should contain their characteristic brain pathology [2]. Antibody response, peripheral Ab levels: Animals will be Confidential Treatment has been requested for portions of this document marked with asterisks. Principal Investigator: Sxxxxxxxxx, Xxxxx, M. bled prior to vaccination, one week following the second immunization, and subsequently every other month, one week following injection. Antibody titers to the antigen and Ab will be determined by serial dilutions of plasma using an ELISA assay as described previously [3]. Measurements of Ab levels in plasma will be performed with Ab1-40/42 kits from Biosource. T-cell response: Which assay to use for this measurement remains to be determined. Behavioral testing: The primates will be assessed daily/weekly for signs of any toxicity, including evaluation of their physical appearance, measurable clinical signs, unprovoked behavior and response to external stimuli. Also, the animals will be weighed periodically. Cognitive testing is also being performed in the old lemur primates by the three-panel runway task ([6;-7]). Animals will be tested before and after immunization in a longitudinal follow-up. Those behavioral studies are performed in the laboratories of Drs. Jxxx-Xxxxxx Xxxxxxx and Nxxxxx Xxxxxx-Xxxxxxx. Brain analysis: The old primates will be killed in the summer of 2006 for analysis of brain pathology. This will include measurements of Ab levels, and stereological assessment of amyloid plaques, microhemorrhages and albumin/IgG infiltration, tau pathology, microglia...
Vaccine Administration. This Supervision Agreement (“Agreement”) is entered into on the effective date of , 2021 between MD/DO (“Supervising Physician”) [the physicians whose signatures appear below, each of which shall be referred to herein as “Supervising Physician”], and , N.D. (“ND”), in order to allow the ND to administer the COVID-19 Vaccination.
